Aim: This study aimed to evaluate the incidence of hypermetabolic axillary lymph nodes due to COVID-19 vaccines and the factors affecting hypermetabolic axillary lymph nodes in F18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in oncology patients.

Patients and Methods: Among the patients who underwent FDG PET/CT in our institution between January 15, 2021, and June 15, 2021, those who received one or two doses of COVID-19 vaccine (CoronaVac or Biontech) were included in the study. Presence and number of ipsilateral hypermetabolic axillary lymph nodes, FDG uptake, and whether there was a difference between these data after the 1st and 2nd vaccination were investigated.

Results: Unilateral hypermetabolic axillary lymph nodes were observed in 9.9% (18/182) of the patients [9.6% (9/94) after 1st dose, 10.2% (9/88) after 2nd dose] vaccinated with CoronaVac; It was detected in 37.5% (9/24) of the patients [35% (7/20) after 1st dose, 50% (2/4) after 2nd dose] who vaccinated with Biontech. A negative correlation was found between the presence of hypermetabolic axillary lymph nodes and age in patients who vaccinated with CoronaVac.

Conclusion: The frequency of hypermetabolic axillary lymph node was lower than that observed after mRNA vaccines, a small group of patients in our study, and lower than reported in the literature. However, the statistical difference could not be evaluated due to the insufficient number of patients in the Biontech group. A brief history of vaccination is recommended before FDG PET/CT to reduce false positives. The potential role of FDG PET/CT in comparing the efficacy of vaccines produced with different biotechnologies should be searched in studies with larger patient populations.

Key words: COVID-19, vaccination, FDG PET/CT, axillary lymphadenopathy, CoronaVac, Biontech

Disclosure: Author has not a financial interest in any of the products, devices, or drugs mentioned in this article. The research was not sponsored by an outside organization. Author has agreed to allow full access to the primary data and to allow the journal to review the data if requested.

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)
INTRODUCTION
Effective and safe vaccination seems to be the best strategy to control the coronavirus disease 2019 (COVID-19) pandemic, which profoundly affects the socioeconomic structure globally and has not yet been discovered an effective antiviral treatment. In addition to vaccines obtained by traditional methods such as inactivated vaccines, live attenuated vaccines, protein-based vaccines, viral vector vaccines, various vaccines have been rapidly developed with intense efforts in new technological platforms using DNA and mRNA fragments. In this direction, mass vaccination of risky groups in Turkey started with CoronaVac (Sinovac Biotech, Beijing, China), an inactive vaccine, on January 13, 2021. As of April 12, Biontech (BNT162b2) vaccines, which are mRNA vaccines, are applied (1).

The most common side effects of vaccines are pain, redness, swelling, itching, weakness, headache, myalgia, fever, chill, nausea, vomiting, diarrhea at the injection site, which resolves within a few days (2-4). In addition, palpable lymphadenopathy on physical examination was reported in the range of 0.1% to 1% after the mRNA vaccines, Biontech and Moderna (mRNA-1273), and the viral vector vaccine Vaxzevria (ChAdOx1-S) (5,6). Studies conducted with F18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) show that unilateral hypermetabolic axillary lymph nodes (HALN) are more common than previously thought (7.4-45.8%) (7-14). FDG PET/CT can detect post-vaccine subclinical reactive lymph nodes much more reliably than CT, magnetic resonance imaging (MRI), and ultrasound (USG) by showing metabolic changes before morphological changes. Therefore, FDG PET/CT studies constitute most cases in which vaccine-related lymphadenopathies are presented in the literature, and higher incidences of HALN are reported with FDG PET/CT compared to clinical studies (5-14).

Among all vaccines, mRNA vaccines provide the highest efficacy against COVID-19 but cause more side effects (2). In contrast, inactivated virus vaccines are the safest but less effective (2). Only two studies have reported lymphadenitis after CoronaVac, with a rate of 0.3-0.7% (15,16). However, there is no study in the literature showing FDG PET/CT hypermetabolic lymph node status after inactive COVID-19 vaccines. Therefore, our research aims to evaluate the frequency of vaccine-related HALNs and the affecting factors in patients who have recently received the CoronaVac vaccine and undergone FDG PET/CT for oncological purposes.

PATIENTS AND METHODS
This retrospective study was conducted with the approval of the ethics committee of our institution (decision no; 2021/3307), with the requirement for informed consent waived. Patients over 18 years old who underwent FDG PET/CT for any indication in our institution between January 15, 2021, and June 15, 2021, who received the first or second dose of the COVID-19 vaccine (CoronaVac or Biontech) in the last month, were included in the study. CoronaVac vaccine contained SARS-CoV-2 antigen (600SU) and aluminum hydroxide (0.45 mg/ml) as an adjuvant (17). The patients' demographic data, medical diagnosis, and treatment histories were obtained from the hospital's digital archive. In addition, information about the date of vaccination, place of vaccination, and vaccine brand was obtained from all patients before imaging. Patients with previous axillary lymph node metastases or who had undergone axillary lymph node dissection and patients with HALNs on their last FDG PET/CT were excluded.

FDG PET/CT Imaging and Analysis
FDG PET/CT imaging was performed according to the European Association of Nuclear Medicine (EANM) guideline using Siemens Biograph 6 TruePoint PET/CT (Siemens, Germany) (18). In brief, 0.14 mCi/kg dose of FDG was administered intravenously to patients who had been fasting for at least six hours and whose blood glucose was <200 mg/dL. After 60 minutes, CT imaging (130 kV, 50 mA) was performed without intravenous contrast, followed by PET images from the head to thigh for 3 minutes at the bedside. PET images were reconstructed using the iterative method. A nuclear medicine physician with 12 years of experience evaluated all PET/CT images. Maximum standardized uptake values (SUVmax) were calculated with a region of interest (ROIs) drawn on bilateral deltoid muscle and axillary lymph nodes. Deltoid and axillary lymph node SUVmax values in the injected arm were considered positive if they were greater than 1.5 times the SUVmax values on the contralateral side (19). If a HALN was detected, the length of its short axis and number were recorded in mm. In addition, the mediastinal blood pool, spleen, and liver SUVmax values of all patients were calculated.

Statistical Analysis
Appropriate descriptive statistics were given for all variables (mean, standard deviation, frequency, and
percentage). T-test and two-way ANOVA tests were used in the analysis of numerical variables. The Chi-square test was used in the analysis of categorical variables. Analyzes were made with the Jamovi 1.8.4.0 program. P <0.05 was considered significant.

RESULTS

Out of 1206 patients who underwent FDG PET/CT in our institution, 206 with suitable characteristics (182 of them CoronaVac, 24 of them Biontech) were included in the study. The flowchart is shown in Figure 1. The median age was 65.8±12.1, and 42% were female. The clinical characteristics of the patients are shown in Table 1. The unilateral HALN was detected in 9.9% (18/182) of patients vaccinated with CoronaVac and 37.5% (9/24) of patients vaccinated with Biontech. Illustrative cases are shown in Figure 2, Figure 3, and Figure 4. With CoronaVac 9.6% (9/94) after 1st dose, 10.2% (9/88) after 2nd dose, with Biontech 35% (7/20) after 1st dose and 50% (2/4) after 2nd dose rate of HALN was seen. Since the number of patients vaccinated with Biontech was meager compared to CoronaVac, a statistical comparison could not be made between the two patient groups. Focal unilateral FDG uptake in the deltoid muscle was detected in 9.3% (17/182) of the patients vaccinated with CoronaVac and 16.7% (4/24) of the patients vaccinated Biontech. All patients with asymmetric FDG uptake in the deltoid muscle had less than 14 days between FDG PET/CT and vaccination time. There was no statistically significant difference in the rates of HALN, rates of FDG uptake in the deltoid muscle, SUVmax values of all lymph nodes, and the number and size of HALNs in patients who underwent FDG PET/CT after the 1st and the 2nd dose CoronaVac. SUVmax values of HALNs were statistically higher after the 2nd dose (1.87±0.74) than after the 1st dose (1.48±0.74) (p=0.014) (Table 2).

Table 1. Clinical characteristics of patients

| All vaccinated n=206 | with CoronaVac n=182 | with Biontech n=24 |
|----------------------|----------------------|---------------------|
| Age                  | 65.8±12.1            | 66.4±11.6           | 60.8±14.3 |
| Gender               |                      |                     |           |
| Female               | 87 (42.2%)           | 73 (40.1%)          | 14 (58.3%) |
| Male                 | 119 (57.8%)          | 109 (59.9%)         | 10 (41.7%) |
| Dose 1               | 114 (55.3%)          | 94 (51.6%)          | 20 (83.3%) |
| Dose 2               | 92 (44.7%)           | 88 (48.4%)          | 4 (16.7%)  |
| Primer               |                      |                     |           |
| Lung cancer          | 44 (21.3%)           | 41 (22.5%)          | 3 (12.5%)  |
| Gastrointestinal cancer | 33 (16.0%)        | 27 (14.8%)          | 6 (25%)    |
| Breast cancer        | 26 (12.6%)           | 20 (11.0%)          | 6 (25%)    |
| Genitourinary cancer | 25 (12.1%)           | 22 (12.1%)          | 3 (12.5%)  |
| Lymphoma             | 17 (8.2%)            | 15 (8.2%)           | 2 (8.3%)   |
| Head and neck cancer | 11 (5.3%)            | 11 (6.0%)           | 0          |
| Gynecological cancer | 9 (4.3%)             | 9 (4.9%)            | 0          |
| Malignant melanoma   | 8 (3.9%)             | 8 (4.4%)            | 1 (4.2%)   |
| Soft tissue sarcoma  | 6 (2.9%)             | 4 (2.2%)            | 2 (8.3%)   |
| Other malignancies   | 26 (12.6%)           | 25 (13.7%)          | 1 (4.2%)   |
| Indications          |                      |                     |           |
| Referred for staging | 72 (34.9%)           | 65 (35.7%)          | 7 (29.2%)  |
| Referred for follow-up | 134 (65.0%)  | 117 (64.3%)         | 17 (70.8%) |

Figure 1. Flow chart showing the inclusion and exclusion criteria of patients
There was no difference between patients with and without HALN in terms of gender, deltoid muscle involvement, spleen, liver, and mediastinal blood pool SUVmax values; there was a difference in terms of age (p=0.02) (Table 3). HALN was detected in 5% of patients over 65 years of age and in 15.9% of patients under 65 years of age who were vaccinated with CoronaVac. HALN was detected in 25% of patients over 65 and 43.8% of patients under 65 years of age who vaccinated with Biontech (Table 4). The mean SUVmax value of HALNs in patients vaccinated with CoronaVac was 1.67±0.75; The mean SUVmax values of HALNs in patients vaccinated with Biontech were 2.44±1.43 (Figure 5).

### Table 2. FDG PET/CT data after 1st and 2nd doses of CoronaVac (*P<0.05)*

|          | All patient n=182 | Dose-1 n=94 | Dose-2 n=88 | P     |
|----------|-------------------|-------------|-------------|-------|
| HALN     | 18 (9.9%)         | 9 (9.6%)    | 9 (10.2%)   | 0.883 |
| Deltoid  | 17 (9.3%)         | 6 (6.4%)    | 11 (12.5%)  | 0.156 |
| SUVmax all | 1.02±0.4         | 0.98±0.37   | 1.06±0.43   | 0.159 |
| SUVmax HALN | 1.67±0.75       | 1.48±0.74   | 1.87±0.74   | 0.014*|
| Diameter LN | 6.8±1.4         | 6.67±1.22   | 6.89±1.62   | 0.747 |
| Number LN  | 1.4±0.5          | 1.22±0.44   | 1.56±0.53   | 0.165 |

FDG PET/CT: F18-fluorodeoxyglucose positron emission tomography/computed tomography, HALN: hypermetabolic axillary lymph node, LN: lymph node, SUVmax: Maximum standardized uptake value

DISCUSSION

While globally mass vaccination studies continue in the struggle against COVID-19, the accumulation of data on the efficacy and safety of vaccines developed with different technologies continues. In this context, in our study, we observed ipsilateral HALN in 9.9% of patients after CoronaVac, which was inactivated coronavirus vaccine. This appears to be lower than previously reported rates of HALN due to mRNA vaccination (7-10,14). We did not detect any difference in the frequency of HALN in FDG PET/CTs performed after the 1st and 2nd doses of vaccination. However, SUVmax values of HALNs after the 2nd dose were
significantly higher than the SUVmax values of the HALN after the 1st dose. Transient inflammation caused by vaccination in lymph nodes may cause false positivities in FDG PET/CT. This can pose a clinical challenge in managing oncology patients who constituted most FDG PET/CT indications. This problem becomes more prominent, especially in malignancies that have a higher risk of spreading to axillary and cervical supraclavicular lymph nodes, such as breast cancer, lymphoma, lung cancer, malignant melanoma, head and neck tumor. In a very recent publication, Skawran et al. (14) reported that they saw HALN in 54% (75/140) of oncology patients who received mRNA vaccine for COVID-19 and that HALN affected clinical management in 12% of patients (17/140). The Breast Imaging Society recommends deferring scans to 4-6 weeks after vaccination if possible and if will not cause a delay (20). However, this delay cannot be tolerated in most patients who performed FDG PET/CT. If unilateral lymphadenopathy is detected within one month after vaccination, a follow-up of 4-12 weeks is recommended (20). We consider that the scope of current recommendations may change as information on the incidence and visualization times of hypermetabolic lymph nodes observed in FDG PET/CT accumulates.

Aside from the confusion caused by HALN in FDG PET/CT in oncology patients, this entity can increase knowledge about vaccine response by visualizing the

### Table 3. Demographic and FDG PET/CT data of patients with and without HALN vaccinated with CoronaVac (*P<0.05)

|                          | Positive HALN n=18 | Negative HALN n=164 | P       |
|--------------------------|--------------------|----------------------|---------|
| Age                      | 60.67±11.56        | 67.05±11.46          | 0.026*  |
| Gender F/M               | 5/13               | 68/96                | 0.261   |
| Deltoid SUVmax           | 1.32±0.41          | 1.31±0.35            | 0.88    |
| Spleen SUVmax            | 3.01±0.47          | 3.14±0.70            | 0.43    |
| Liver SUVmax             | 4.12±0.84          | 4.07±0.97            | 0.828   |
| Mediastinum SUVmax       | 2.72±0.51          | 2.94±0.70            | 0.2     |

F/M: Female/Male, FDG PET/CT: F18-fluorodeoxyglucose positron emission tomography/computed tomography, HALN: hypermetabolic axillary lymph node, LN: lymph node, SUVmax: Maximum standardized uptake value

**Figure 4.** A; FDG uptake in the deltoid muscle in the PET/CT MIP image on the 6th day after two doses of CoronaVac of a 64-year-old patient diagnosed with bladder cancer (SUVmax: 2.34). B; FDG uptake in the deltoid muscle in the FDG PET/CT MIP image of a 58-year-old patient who was diagnosed with Kaposi’s sarcoma and had the 1st dose of Biontech vaccine six days ago (SUVmax: 2.16)

**Figure 5.** HALN SUVmax levels of patients vaccinated with CoronaVac and Biontech.
spatial and temporal dynamics of immune cells in the host body after vaccination (21). It is still premature to say that this imagined inflammatory response is correlated with the vaccine’s efficacy. However, the fact that 26-54% HALN rates reported in mRNA vaccines (7-10,14) are higher (5-29%) than those previously reported with inactive virus vaccines, unadjuvanted seasonal influenza virus vaccine (22) and H1N1 vaccine (23), supports this idea. In addition, Cohen et al., in their study on HALN in FDG PET/CT on patients with hematological malignancies who received mRNA vaccine, also performed an additional serological test in a subgroup (9). Accordingly, they found a statistically significant positive correlation between the presence of HALN and the anti-spike antibody titer, showing that HALN had 90% PPV in predicting serology positivity. However, they stated that their data were valid only in patients with hematological malignancies and that the absence of VAHL could not yet be said to be an indicator of impaired humoral response (9).

While studies investigating the presence of HALN in patients who were vaccinated with COVID-19 vaccines produced with mRNA technology constitute almost all of the literature in this area, there is no study yet showing the presence/frequency of lymphadenopathy in inactivated coronavirus vaccines. In our cohort, which represents the first study in this area, a shallow rate of 10% was detected compared to the frequency of HALN given in mRNA vaccines in the literature. In our research, we found higher rates of HALN in a small number of Biontech-vaccinated patients, but the patient population was not sufficient to perform statistical analysis between the two groups. Nevertheless, our data support the thesis that mRNA vaccines are more immunogenic than conventional vaccines and potentially responsible for the presence of HALN. Larger patient populations are needed to evaluate the frequency and intensity of HALN in vaccines produced with different biotechnologies, and prospective studies supported by serology are required to more clearly determine the relationship between HALN and the efficacy of the vaccine. Similar to mRNA vaccines, an inverse relationship was found between increasing age and the frequency of HALN in our study (p=0.026) (7,8,10). This situation can be explained by the decrease in primary and secondary antibody responses with aging (fewer cells produce specific antibodies, fewer antibodies are produced per cell, and antibodies are less effective in preventing infection, even with sufficient antibodies) (10, 24).

There were some limitations in our study. We could not statistically compare the frequency of HALN after Biontech and CoronaVac, as we did not have enough patients vaccinated with Biontech. Since our patient group consisted of only oncology patients, there may exist publication bias. Vaccine-related HALN is based solely on clinical observation, and pathological confirmation was not performed in any patient.

**CONCLUSION**

The frequency of HALN, which can cause false positives in FDG PET/CT, is lower with inactivated Coronavirus vaccine than with mRNA vaccines. We recommend including the information about the time of vaccination, the brand, and localization of the vaccine in the anamnesis taken from the patients before imaging, and the physician interprets in the light of this information. In addition, if the patient has a known lateraledized upper body malignancy at the time of vaccination, choosing the opposite arm for vaccination will reduce confusion on this issue. The clinical value of FDG PET/CT in demonstrating the efficacy of vaccines produced with different biotechnologies is an exciting and important area that needs to be investigated with more data.

| Table 4. HALN rates in patients over 65 years of age and under |
|---------------------------------------------------------------|
|                  | Over 65 years n=108 | Under 65 year n=98 | Total n=206 |
| Biontech          |                      |                    |             |
| Positive          | 2 (25%)              | 7 (43.8%)          | 9 (37.5%)   |
| Negative          | 6 (75%)              | 9 (56.2%)          | 15 (62.5%)  |
| Total             | 8 (100%)             | 16 (100%)          | 24 (100%)   |
| CoronaVac         |                      |                    |             |
| Positive          | 5 (5%)               | 13 (15.9%)         | 18 (9.9%)   |
| Negative          | 95 (95%)             | 69 (84.1%)         | 164 (90.1%) |
| Total             | 100 (100%)           | 82 (100%)          | 182 (100%)  |

HALN: hypermetabolic axillary lymph node
Conflict of interest: Authors declare that there is no conflict of interest between the authors of the article.

Financial conflict of interest: Authors declare that they did not receive any financial support in this study.

Address correspondence to: Ozlem Sahin, Necmettin Erbakan University, Meram Faculty of Medicine, Department of Nuclear Medicine, Konya, Turkey e-mail: drozlem_sahin@gmail.com

REFERENCES

1. COVID-19 Aşışı ulusal uygulama stratejisi, T.C. Sağlık Bakanlığı COVID-19 Aşışı bilgilendirme platformu. 4 Temmuz 2021’de ulaşıldı. https://covid19asi.saglik.gov.tr/TR-77706/covid-19-asisi-ulusal-uygulama-stratejisi.html

2. Cheng H, Peng Z, Luo W, et al. Efficacy and safety of COVID-19 vaccines in phase III trials: A meta-analysis. Vaccines 2021; 9:582.

3. Palacios R, Patino EG, de Oliveira Piorelli R, et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (Inactivated) vaccine manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials 2020;15;21:853.

4. Keshavarz P, Yazdanpanah F, Rafiee F, et al. Lymphadenopathy following COVID-19 vaccination: Imaging findings review. Acad Radiol 2021;28(8):1058-71.

5. Brown A, Shah S, Dluzewski S, et al. Unilateral axillary adenopathy following COVID-19 vaccination: A multimodality pictorial illustration and review of current guidelines. Clin Radiol 2021;76:553-8.

6. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-15.

7. Bernstein H, Priss M, Anati T, et al. Axillary lymph nodes hypermetabolism after BNT162b2 mRNA COVID-19 vaccination in cancer patients undergoing 18F-FDG PET/CT: A cohort study. Clin Nucl Med 2021;46:396-401.

8. Cohen D, Krauthammer SH, Wolf I, et al. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: Incidence assessed by [18F]FDG PET-CT and relevance to study interpretation. Eur J Nucl Med Mol Imaging 2021;48:1854-63.

9. Cohen D, Krauthammer SH, Cohen YC, et al. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. Eur J Nucl Med Mol Imaging 2021;8:1-10.

10. Eifer M, Tau N, Alhoubani Y, et al. COVID-19 mRNA vaccination: Age and immune status and its association with axillary lymph node PET/CT uptake. J Nucl Med 2021;23:jnumed.121.262194.

11. Eshet Y, Tau N, Alhoubani Y, et al. Prevalence of increased FDG PET/CT axillary lymph node uptake beyond 6 weeks after mRNA COVID-19 vaccination. Radiology 2021;27:210886.

12. Schroeder DG, Jang S, Johnson DR, et al. Frequency and characteristics of nodal and deltoid FDG and 11C-Choline uptake on PET imaging performed after COVID-19 vaccination. AJR Am J Roentgenol 2021 May 19. doi: 10.2214/AJR.21.25928.

13. Shin M, Hyun CY, Choi YH, et al. COVID-19 vaccination-associated lymphadenopathy on FDG PET/CT: Distinctive features in adenovirus-vectorized vaccine. Clin Nucl Med 2021 Jun 10. doi: 10.1097/RLU.0000000000003800.

14. Skawran S, Gennari AG, Dittli M, et al. [18F]FDG uptake of axillary lymph nodes after COVID-19 vaccination in oncological PET/CT: Frequency, intensity, and potential clinical impact. Eur Radiol 2021;22:1-9.

15. Zhang MX, Zhang TT, Shi GF, et al. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021;13:1-8.

16. Djanas D, Yusirwan, Martini RD, et al. Survey data of COVID-19 vaccine side effects among hospital staff in a national referral hospital in Indonesia. Data Brief 2021;36:107098.

17. İnanıf Pandemik COVID-19 aşısı CoronaVac’ın içeriği nedir? T.C. Sağlık Bakanlığı COVID-19 Aşısı Bilgilendirme Platformu. 4 Temmuz 2021’de ulaşıldı. https://covid19asi.saglik.gov.tr/TR-78241/inaft-f-pandemik-covid-19-asisi-coronavac-icerigi-nedir.html

18. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0. Eur J Nucl Med Mol Imaging 2015;42:328-54.

19. Thomsassen A, Lerberg Nielsen A, Gerke O, et al. Duration of 18F-FDG avidity in lymph nodes after pandemic H1N1v and seasonal influenza vaccination. Eur J Nucl Med Mol Imaging 2011;38:894-8.

20. The society of breast Imaging patient care and delivery committee. SBI recommendations for the management of axillary adenopathy in patients with recent COVID-19 vaccination. Updated January 16, 2021. Accessed July 03, 2021. https://www.sbionline.org/Portals/0/Position%20Statements/2021/SBI-recommendations-for-managing-axillary-adenopathy-post-COVID-vaccination.pdf

21. Yoon H, Hong KJ. Non-invasive molecular imaging of immune cell dynamics for vaccine research. Clin Exp Vaccine Res 2019;8:89-93.

22. Shirone N, Shinkai T, Yamane T, et al. Axillary lymph node accumulation on FDG-PET/CT after influenza vaccination. Ann Nucl Med 2012;26:248-52.

23. Burger IA, Husmann L, Hany TF, et al. Incidence and intensity of F-18 FDG uptake after vaccination with H1N1v and seasonal influenza vaccination. Eur J Nucl Med Mol Imaging 2011;38:894-8.

24. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000;31:578-85.